All In Biotech

Drug Trial Radar · NCT07387926

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Open-label, Phase I/II Study to Evaluate Safety and Efficacy of Asciminib With Chemotherapy Followed by Asciminib Plus Blinatumomab in Pediatric, Adolescent, and Young Adults With Relapsed or Refractory BCR::ABL1-positive (Philadelphia Positive, Ph+) or BCR::ABL1-like (Ph-like) ALL

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jul 5, 2026

Primary completion

Sep 19, 2033

Study completion May 30, 2036

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion. Part 1 dose escalation will enroll participants aged ≥1 year to ≤30 years to determine the recommended phase 2 dose (RP2D) of asciminib when administered with low intensity chemotherapy. Part 2 dose expansion will enroll participants aged ≥1 year to ≤30 years to evaluate safety, tolerability, and efficacy of asciminib at the RP2D with the treatment regimen.

Conditions

  • Acute Lymphoblastic Leukemia
  • Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Interventions

  • Asciminib Adult formulationDrug

    oral, administered daily (twice daily for participants with known T315I mutation); Cycles 1, 2, 3

  • Asciminib Pediatric formulationDrug

    oral, administered daily (twice daily for participants with known T315I mutation); Cycles 1, 2, 3

  • DexamethasoneDrug

    Fixed doses, oral (preferred) or intravenous (IV) twice daily; Cycle 1, Days 1 - 14; (Cycle 1 = 28 days)

  • VincristineDrug

    Fixed doses, IV, weekly; Cycle 1

  • BlinatumomabDrug

    Dosing based on bone marrow disease burden and weight. Continuous IV infusion; Cycles 2, 3

  • Methotrexate (intrathecal)Drug

    Intrathecal

  • Cytarabine (intrathecal)Drug

    Intrathecal

  • Hydrocortisone (intrathecal)Drug

    Intrathecal

  • Prednisolone (intrathecal)Drug

    Intrathecal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) occurring during cycle 1 (debulking induction)Time frame: During Cycle 1 (Cycle 1 = 28 days)
  2. Part 1 Dose Escalation: Incidence and severity of adverse events (AEs) during cycle 1 (debulking induction)Time frame: During Cycle 1 (Cycle = 28 days)
  3. Part 2 Dose Expansion: Percentage of complete response/remission (CR) evaluable participants who achieve CR treated at recommended phase 2 dose (RP2D) (debulking induction)Time frame: End of Cycle 1 (Cycle 1 = 28 days)

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Sydney, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Brisbane, Queensland, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Marseille, France · Recruiting

  • Novartis Investigative Site

    Ramat Gan, Israel · Recruiting

  • Novartis Investigative Site

    Utrecht, Netherlands · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.